Pharmaceuticals - Toronto, Ontario, Canada
For nearly half a century medicinal chemists have sought to incorporate the benefits of fluorine into a broader range of drug structures. In carefully defined conditions, fluorine can improve potency, stability and safety, and other critical drug attributes. Innovative breakthroughs by Fluorinov Pharma enable fluorine chemical synthesis never before possible and have the potential to transform promising compounds into superior drugs. Integrating insights from validated, clinically active compounds, with the Fluorinov Discovery Platform, this strategy rapidly yields a rich pipeline of lower-risk NCEs with superior properties. Fluorinov has a deep portfolio of potential best-in-class drug candidates with attractive therapeutic profiles in oncology (multiple myeloma, pancreatic cancer and glioblastoma) and central nervous system (CNS) disorders and rare cancers. The Fluorinov team benefits from longstanding collaborations with and investments by the Ontario Institute for Cancer Research, US National Institutes of Health, US National Cancer Institute, Ontario Brain Institute, National Research Council, Princess Margaret Cancer Centre and other leading institutions (www.fluorinovpharma.com).